| scholarly article | Q13442814 |
| P50 | author | Eva Martínez-Pinilla | Q42096031 |
| José L. Lanciego | Q38327539 | ||
| Rafael Franco | Q40238726 | ||
| Salvador Sierra | Q42096022 | ||
| P2093 | author name string | Alberto J Rico | |
| Natasha Luquin | |||
| Elvira Roda | |||
| Iria G Dopeso-Reyes | |||
| José L Labandeira-García | |||
| Virginia Gómez-Bautista | |||
| Alfonso Vázquez | |||
| P2860 | cites work | The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in Basal Ganglia | Q21131063 |
| Localization and function of the cannabinoid CB1 receptor in the anterolateral bed nucleus of the stria terminalis | Q21142667 | ||
| Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers | Q24304896 | ||
| Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations | Q24309438 | ||
| Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay | Q24312603 | ||
| Building a new conceptual framework for receptor heteromers | Q24644975 | ||
| Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth | Q24656080 | ||
| Opioid receptor heteromers in analgesia | Q27004306 | ||
| Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons | Q28144567 | ||
| Role of endogenous cannabinoids in synaptic signaling | Q28185075 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors | Q28251504 | ||
| Cannabinoid signalling | Q28267949 | ||
| Role of CB2 receptors in neuroprotective effects of cannabinoids | Q28269610 | ||
| Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study | Q28273200 | ||
| Identification and functional characterization of brainstem cannabinoid CB2 receptors | Q28276972 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism | Q28328337 | ||
| Circadian-related heteromerization of adrenergic and dopamine D₄ receptors modulates melatonin synthesis and release in the pineal gland | Q28480542 | ||
| Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus | Q28579094 | ||
| The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling | Q28645703 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain | Q30047898 | ||
| Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. | Q51976878 | ||
| GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. | Q52023779 | ||
| Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. | Q52144462 | ||
| Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. | Q52578470 | ||
| Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin | Q60678303 | ||
| Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats | Q64814751 | ||
| Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study | Q72656516 | ||
| Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study | Q81630893 | ||
| Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes | Q84093381 | ||
| The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats | Q42445636 | ||
| A direct projection from the subthalamic nucleus to the ventral thalamus in monkeys | Q42471175 | ||
| Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis | Q42471782 | ||
| Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia | Q42486484 | ||
| Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys | Q42487098 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. | Q42488876 | ||
| The basal ganglia and thalamus of the long-tailed macaque in stereotaxic coordinates. A template atlas based on coronal, sagittal and horizontal brain sections | Q42552747 | ||
| Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate-putamen nucleus | Q43856112 | ||
| Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease | Q44285779 | ||
| Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. | Q44334367 | ||
| Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens | Q44345871 | ||
| Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism | Q44418544 | ||
| Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia | Q44451116 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. | Q44681104 | ||
| Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors | Q45153412 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. | Q46639969 | ||
| A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain | Q48150235 | ||
| Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen | Q48189572 | ||
| Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. | Q48608235 | ||
| Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis | Q48655780 | ||
| Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. | Q48837860 | ||
| L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus | Q48873583 | ||
| Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures | Q48963650 | ||
| CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 | ||
| Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex | Q33293523 | ||
| Motor actions of cannabinoids in the basal ganglia output nuclei | Q33720160 | ||
| Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex | Q34001324 | ||
| GABAergic and cortical and subcortical glutamatergic axon terminals contain CB1 cannabinoid receptors in the ventromedial nucleus of the hypothalamus. | Q34056106 | ||
| Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas | Q34300051 | ||
| The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons | Q34380089 | ||
| CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. | Q34504178 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| The cannabinoid system and immune modulation | Q35213813 | ||
| Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors | Q35807657 | ||
| Cannabinoid signaling in glial cells | Q35897353 | ||
| Distribution of CB1 cannabinoid receptors and their relationship with mu-opioid receptors in the rat periaqueductal gray | Q36007619 | ||
| Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. | Q36075529 | ||
| CB₂ cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. | Q36083691 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Intracellular trafficking of RNA in neurons | Q36630186 | ||
| Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain | Q36653994 | ||
| Cannabinoid CB2 receptor: a new target for controlling neural cell survival? | Q36671508 | ||
| Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum | Q36812016 | ||
| Presynaptic modulation by endocannabinoids | Q37026723 | ||
| Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 | Q37132571 | ||
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. | Q37253331 | ||
| Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands | Q38107222 | ||
| Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. | Q38322450 | ||
| Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 | ||
| Cannabinoid receptors CB1 and CB2 form functional heteromers in brain | Q39359086 | ||
| Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! | Q39992733 | ||
| Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system | Q40935147 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| parkinsonian syndrome | Q1531991 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | 2721-2738 | |
| P577 | publication date | 2014-06-28 | |
| P1433 | published in | Brain Structure and Function | Q13444883 |
| P1476 | title | Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism | |
| P478 | volume | 220 |
| Q50045463 | Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims. |
| Q48242279 | Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. |
| Q43217955 | Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors. |
| Q30392902 | CB2 Cannabinoid Receptor Knockout in Mice Impairs Contextual Long-Term Memory and Enhances Spatial Working Memory |
| Q55513558 | Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. |
| Q47850781 | Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease |
| Q38563981 | Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications |
| Q42258332 | Cannabinoids in Parkinson's Disease |
| Q37659341 | Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis |
| Q49754648 | Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay |
| Q67496249 | Effects of Cocaine Self-Administration and Its Extinction on the Rat Brain Cannabinoid CB1 and CB2 Receptors. |
| Q28272826 | Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats |
| Q37489251 | G Protein-Coupled Receptor Heteromers. |
| Q92535750 | Harmful Effects of Smoking Cannabis: A Cerebrovascular and Neurological Perspective |
| Q38604909 | Interaction between Cannabinoid Type 1 and Type 2 Receptors in the Modulation of Subventricular Zone and Dentate Gyrus Neurogenesis |
| Q38796819 | JWH-133, a Selective Cannabinoid CB₂ Receptor Agonist, Exerts Toxic Effects on Neuroblastoma SH-SY5Y Cells |
| Q39509266 | Multivariate Imaging Genetics Study of MRI Gray Matter Volume and SNPs Reveals Biological Pathways Correlated with Brain Structural Differences in Attention Deficit Hyperactivity Disorder |
| Q39405720 | Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation |
| Q37029175 | Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus |
| Q90248156 | Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q28073952 | Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders |
| Q39392775 | Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease |
| Q100464821 | The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders |
| Q35171113 | The therapeutic potential of cannabinoids for movement disorders |
Search more.